莫西沙星治疗老年社区获得性肺炎的临床对照试验

目的评价莫西沙星在社区获得性肺炎（CAP）老年人群中的疗效和安全性。方法采用前瞻性设计，将100例老年病人随机分为治疗组（52例）和对照组（48例），治疗组予莫西沙星片0．4g，po，qd，疗程14d。对照组于头孢呋新针2．5g，iv，bid，联用克拉霉素片0．25g，po，bid，疗程14d。或单用克拉霉素片5．0g，po，bid，疗程14d。统计分析治愈率、症状缓解时间、不良反应等。结果疗程结束后，治疗组和对照组治愈率分别为87％和88％，差异无显著意义（P〉0．05）。但在疗程早期（D3、D5）治疗组治愈率高于对照组有显著差异（P〈0．05）。治疗组多种症状（发热、咳嗽、痰液性状改善、胸痛等）缓解时间更短有显著意义（P〈0．01，P〈0.05）。不良反应少，均可耐受。本次试验病原体检出率低（27．9％）。结论莫西沙星治疗老年CAP病人临床疗效肯定，安全，给药方便。

Controlled clinical trials of moxifloxacin in old patients with community-acquired pneumonia

Objective To evaluate the efficiency and safety of moxifloxacin in old patients with community-acquired pneumonia (CAP). Methods A prospective design was conducted. 100 old patients with CAP were randomly divided into trial group and control group. The 52 trial group members were treated with moxifloxacin administering 0.4 g, po,qd for 14 d. In the control group, 43 patients were treated with ceforuxime injection administering 2.5 g, iv, bid and clalithromycin 0.25 g, po,bid for 14 d. Statistical difference was analyzed in terms effectiveness, side effects and compliance and the comparisons were made between the groups. Results After treatment, the total cured rate for the trail group was 87%, while for the control group it was 88%:P>0.05. However, the group difference in the cured rates on d 3 and d 5 were significant (P<0.05) in favor of the trial group. The clinical sign symptom such as fever,cough and chest pain in the trail group were alleviated significantly earlier than that in the control group(P values ranged between less than 0.01 and less than 0.05). A few side effects cause by moxifloxacin were recorded. Specific pathogens of CAP could only be found in 27.9% of the patients. Conclusions Moxifloxacin is effective , safe and convenient in use for old patients with CAP.